Developing macromolecular therapeutics: The future drug-of-choice

Frontiers of Chemical Engineering in China

Volumn 4, Issue 1, 2010, Pages 10-17

  He, Huining ^a,b   Dong, Weibing ^a   Gong, Junbo ^a   Wang, Jingkang ^a   Yang, Victor C ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Drug delivery systems; Macromolecular drugs; Therapeutic efficacy

Indexed keywords

EID: 77952887464     PISSN: 16737369     EISSN: 16737474     Source Type: Journal    
DOI: 10.1007/s11705-009-0291-5     Document Type: Review

References (82)

1. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev, 2002, 54: 631-651.
2. Dreher M R, Liu W, Michelich C R, Dewhirst M W, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst, 2006, 98: 335-344.
3. Maeda H, Seymour L W, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem, 2002, 3: 351-362.
4. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit Rev in Oncol Hematol, 1995, 18: 207-231.
5. Defoort J P, Nardelli B, Huang W, Ho D D, Tam J P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc Natl Acad Sci USA, 1992, 89: 3879-3883.
6. Hamajima K, Bukawa H, Fukushima J, Kawamoto S, Kaneko T, Sekigawa K I, Tanaka S I, Tsukuda M, Okuda K. A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation method with strong immunogenicity for HIV-1. Clin Immunol Immunopathol, 1995, 77: 374-379.
7. Greenberg S, Frishman W. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol, 1990, 30: 596-608.
8. Torchilin V P. Targeting of drugs and drug carriers within the cardiovascular system. Adv Drug Delivery Rev, 1995, 17: 75-101.
9. Chang C-T L, Liou H-Y, Tang H L, Sung H Y. Activation, purification and properties of beta-amylase from sweet potatoes (Ipomoea batatas). Biotechnol Appl Biochem, 1996, 24: 13-18.
10. Noda T, Furuta S, Suda I. Sweet potato [beta]-amylase immobilized on chitosan beads and its application in the semi-continuous production of maltose. Carbohydr Polym, 2001, 44: 189-195.
11. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem, 1992, 205: 263-270.
12. Chen C, Ridzon D A, Broomer A J, Zhou Z, Lee D H, Nguyen J T, Barbisin M, Xu N L, Mahuvakar V R, Andersen M R, Lao K Q, Livak K J, Guegler K J. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucl Acids Res, 2005, 33: e179.
13. Gibson U E, Heid C A, Williams P M. A novel method for real time quantitative RT-PCR. Genome Res, 1996, 6: 995-1001.
14. Siebert P D, Chenchik A, Kellogg D E, Lukyanov K A, Lukyanov S A. An improved PCR method for walking in uncloned genomic DNA. Nucl Acids Res, 1995, 23: 1087-1088.
15. Gerrard A J, Hudson D L, Brownlee G G, Watt F M. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet, 1993, 3: 180-183.
16. Pipe S W. Coagulation factors with improved properties for hemophilia gene therapy. Semin Thromb Hemost, 2004, 30: 227-237.
17. Suh J S, Lee J Y, Choi Y S, Yu F, Yang V, Lee S J, Chung C P, Park Y J. Efficient labeling of mesenchymal stem cells using cell permeable magnetic nanoparticles. Biochem Biophys Res Commun, 2009, 379: 669-675.
18. Allen T M, Cullis P R. Drug delivery systems: entering the mainstream. Science, 2004, 303: 1818-1822.
19. Creque H M, Langer R, Folkman J. One month of sustained release of insulin from a polymer implant. Diabetes, 1980, 29: 37-40.
20. Drummond D C, Meyer O, Hong K, Kirpotin D B, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 1999, 51: 691-744.
21. Harrington K J, Lewanski C R, Stewart J S W. Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development. Clin Oncol, 2000, 12: 2-15.
22. Lukyanov A N, Elbayoumi T A, Chakilam A R, Torchilin V P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Controlled Release, 2004, 100: 135-144.
23. Templeton N S, Lasic D D, Frederik P M, Strey H H, Roberts D D, Pavlakis G N. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotech, 1997, 15: 647-652.
24. Barichello J M, Morishita M, Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm, 1999, 25: 471-476.
25. Deamer D W, Barchfeld G L. Encapsulation of macromolecules by lipid vesicles under simulated prebiotic conditions. J Mol Evol, 1982, 18: 203-206.
26. Grenha A, Seijo B, Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci, 25: 427-437.
27. Radtchenko I L, Sukhorukov G B, Möhwald H. Incorporation of macromolecules into polyelectrolyte micro- and nanocapsules via surface controlled precipitation on colloidal particles. Colloids SurfA, 2002, 202: 127-133.
28. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar M. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res, 2006, 23: 184-195.
29. Carino G P, Jacob J S, Mathiowitz E. Nanosphere based oral insulin delivery. J Controlled Release, 2000, 65: 261-269.
30. Lowman A M, Morishita M, Kajita M, Nagai T, Peppas N A. Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci, 1999, 88: 933-937.
31. Liu X, Pettway G J, McCauley L K, Ma P X. Pulsatile release of parathyroid hormone from an implantable delivery system. Biomaterials, 2007, 28: 4124-4131.
32. Song H, Liang J F, Yang V C. A prodrug approach for delivery of t-PA: construction of the cationic t-PA prodrug by a recombinant method and preliminary in vitro evaluation of the construct. ASAIO J, 2000, 46: 663-668.
33. Duncan R. Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharmaceut Sci Tech Today, 1999, 2: 441-449.
34. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advances in Enzyme Regulation, 2001, 41: 189-207.
35. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. Journal of Controlled Release, 2001, 74: 47-61.
36. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of Controlled Release, 2000, 65: 271-284.
37. Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Cancer Science, 2001, 92: 439-451.
38. Ahmad I, Longenecker M, Samuel J, Allen T M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res, 1993, 53: 1484-1488.
39. Baselga J, Norton L, Albanell J, Kim Y M, Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptinTM) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 1998, 58: 2825-2831.
40. Tardi P, Boman N, Cullis P. Liposomal doxorubicin. Journal of Drug Targeting, 1996, 4: 129-140.
41. Yang H M, Reisfeld R A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA, 1988, 85: 1189-1193.
42. Davis TA, Grillo-Lopez A J, White C A, McLaughlin P, Czuczman M S, Link B K, Maloney D G, Weaver R L, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in nonhodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol, 2000, 18: 3135-3143.
43. Davis T A, White C A, Grillo-Lopez A J, Velasquez W S, Link B, Maloney D G, Dillman R O, Williams M E, Mohrbacher A, Weaver R, Dowden S, Levy R. Single-agent monoclonal antibody efficacy in bulky non-hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol, 1999, 17: 1851-1857.
44. Jazirehi A R, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene, 2005, 24: 2121-2143.
45. Maloney D G, Grillo-Lopez A J, White C A, Bodkin D, Schilder R J, Neidhart J A, Janakiraman N, Foon K A, Liles T M, Dallaire B K, Wey K, Royston I, Davis T, Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 1997, 90: 2188-2195.
46. Witzig T E, Flinn IW, Gordon L I, Emmanouilides C, Czuczman M S, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani P S, White C A. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 2002, 20: 3262-3269.
47. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials, 2006, 27: 3482-3490.
48. Lassalle V, Ferreira M L. PLA nano- and microparticles for drug delivery: an overview of the methods of preparation. Macromolecular Bioscience, 2007, 7: 767-783.
49. Munier S, Messai I, Delair T, Verrier B, Ataman-Önal Y. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. Colloids and Surfaces B: Biointerfaces, 2005, 43: 163-173.
50. Elvassore N, Bertucco A, Caliceti P. Production of insulin-loaded poly(ethylene glycol)/poly(1-lactide) (PEG/PLA) nanoparticles by gas antisolvent techniques. J Pharm Sci, 2001, 90: 1628-1636.
51. Janes K A, Calvo P, Alonso M J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Delivery Rev, 2001, 47: 83-97.
52. Chertok B, David A E, Moffat B A, Yang V C. Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials, 2009, 30: 6780-6787.
53. Huang M, Qiao Z, Miao F, Jia N, Shen H. Biofunctional magnetic nanoparticles as contrast agents for magnetic resonance imaging of pancreas cancer. Microchimica Acta, 2009, 167: 27-34.
54. Zhao M, Kircher M F, Josephson L, Weissleder R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjugate Chemistry, 2002, 13: 840-844.
55. Needham D, Dewhirst M W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Delivery Rev, 2001, 53: 285-305.
56. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Delivery Rev, 2001, 53: 321-339.
57. Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell S J D. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. International Journal of Pharmaceutics, 2004, 277: 91-97.
58. Agnihotri S A, Mallikarjuna N N, Aminabhavi T M. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. Journal of Controlled Release, 2004, 100: 5-28.
59. Ceh B, Winterhalter M, Frederik P M, Vallner J J, Lasic D D. Stealth® liposomes: from theory to product. Adv Drug Delivery Rev, 1997, 24: 165-177.
60. Moghimi S M, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Progress in Lipid Research, 2003, 42: 463-478.
61. Gupta B, Levchenko T S, Torchilin V P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Delivery Rev, 2005, 57: 637-651.
62. Patel L, Zaro J, Shen W C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharmaceutical Research, 2007, 24: 1977-1992.
63. Snyder E, Dowdy S. Cell penetrating peptides in drug delivery. Pharmaceutical Research, 2004, 21: 389-393.
64. Tréhin R, Merkle H P. Chances and pitfalls of cell penetrating peptides for cellular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58: 209-223.
65. Fawell S, Seery J, Daikh Y, Moore C, Chen L L, Pepinsky B, Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA, 1994, 91: 664-668.
66. Frankel A D, Pabo C O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 1988, 55: 1189-1193.
67. Green M, Loewenstein P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell, 1988, 55: 1179-1188.
68. Derossi D, Joliot A H, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. Journal of Biological Chemistry, 1994, 269: 10444-10450.
69. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotech, 1998, 16: 440-443.
70. Byun Y, Chang L C, Lee L M, Han I S, Singh V K, Yang V C. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low molecular weight protamine. ASAIO Journal, 2000, 46: 435-439.
71. Byun Y, Singh V K, Yang V C. Low molecular weight protamine: a potential nontoxic heparin antagonist. Thrombosis Research, 1999, 94: 53-61.
72. Chang L C, Lee H F, Yang Z, Yang V. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): Preparation and characterization. The AAPS Journal, 2001, 3: 7-14.
73. Chang L C, Liang J, Lee H F, Lee L, Yang V. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): In vitro evaluation of efficacy and toxicity. The AAPS Journal, 2001, 3: 15-23.
74. Chang L C, Wrobleski S, Wakefield T, Lee L, Yang V. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): Preliminary in vivo evaluation of efficacy and toxicity using a canine model. The AAPS Journal, 2001, 3: 24-31.
75. Liang J F, Zhen L, Chang L C, Yang V C. A less toxic heparin antagonist-low molecular weight protamine. Biochemistry (Moscow), 2003, 68: 116-120.
76. Park Y J, Chang L C, Liang J F, Moon C, Chung C P, Yang V C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J, 2005, 19: 1555-1557.
77. Park Y J, Liang J F, Ko K S, Kim S W, Yang V C. Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. The Journal of Gene Medicine, 2003, 5: 700-711.
78. Schwarze S R, Ho A, Vocero-Akbani A, Dowdy S F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science, 1999, 285: 1569-1572.
79. Kwon Y M, Li Y, Naik S, Liang J F, Huang Y, Park Y J, Yang V C. The ATTEMPTS delivery systems for macromolecular drugs. Expert Opinion on Drug Delivery, 2008, 5: 1255-1266.
80. Li Y T, Kwon YM, Spangrude G J, Liang J F, Chung H S, Park Y J, Yang V C. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. Journal of Biomedical Materials Research Part A, 2009, 91A: 209-220.
81. Liang J F, Li Y T, Song H, Park Y J, Naik S S, Yang V C. ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs. Journal of Controlled Release, 2002, 78: 67-79.
82. Park Y J, Liang J F, Song H, Li Y T, Naik S, Yang V C. ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects. Adv Drug Delivery Rev, 2003, 55: 251-265.